Anticancer activity of novel unnatural synthetic isoprenoids

Val R. Adams, David L. Deremer, Bojana Stevich, Cynthia A. Mattingly, Becky Gallt, Thangaiah Subramanian, Jerry M. Troutman, H. Peter Spielmann

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: The KRAS oncogene has a high prevalence in solid malignancies. Targeting KRAS and inappropriate activation of the MAPK pathway with novel drugs is of interest. This study developed and screened a library of compounds designed to inhibit KRAS signaling by altering prenyl function. Materials and Methods: To screen a library of novel farnesyl analogs for their anticancer activity in human lung cancer and breast cancer cell lines. To evaluate if the designed and actual pharmacology are congruent. Results: Sixty-seven novel compounds were tested and 70% of them screened positive for activity in at least one cell line. Two active compounds inhibited phosphorylation of MAP kinase consistent with KRAS inhibition. Conclusion: Although 47 of the 67 novel agents screened positive for activity, none of them were highly potent. However, targeting RAS with compounds that compete with farnesyl and geranylgeranyl modification of the protein remains viable and further work is already underway to create second generation molecules.

Original languageEnglish
Pages (from-to)2505-2512
Number of pages8
JournalAnticancer Research
Issue number7
StatePublished - Jul 2010


  • Breast cancer
  • Farnesyl diphosphate analogues
  • Lung cancer
  • RAS protein farnesylation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Anticancer activity of novel unnatural synthetic isoprenoids'. Together they form a unique fingerprint.

Cite this